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Summary
Background Despite declines in deaths from rheumatic heart disease (RHD) in Africa over the past 30 years, it 
remains a major cause of cardiovascular morbidity and mortality on the continent. We present an investment case for 
interventions to prevent and manage RHD in the African Union (AU).
Methods We created a cohort state-transition model to estimate key outcomes in the disease process, including cases 
of pharyngitis from group A streptococcus, episodes of acute rheumatic fever (ARF), cases of RHD, heart failure, and 
deaths. With this model, we estimated the impact of scaling up interventions using estimates of effect sizes from 
published studies. We estimated the cost to scale up coverage of interventions and summarised the benefits by 
monetising health gains estimated in the model using a full income approach. Costs and benefits were compared 
using the benefit–cost ratio and the net benefits with discounted costs and benefits.
Findings Operationally achievable levels of scale-up of interventions along the disease spectrum, including primary 
prevention, secondary prevention, platforms for management of heart failure, and heart valve surgery could avert 
74 000 (UI 50 000–104 000) deaths from RHD and ARF from 2021 to 2030 in the AU, reaching a 30·7% (21·6–39·0) 
reduction in the age-standardised death rate from RHD in 2030, compared with no increase in coverage of 
interventions. The estimated benefit–cost ratio for plausible scale-up of secondary prevention and secondary and 
tertiary care interventions was 4·7 (2·9–6·3) with a net benefit of $2·8 billion (1·6–3·9; 2019 US$) through 2030. The 
estimated benefit–cost ratio for primary prevention scale-up was low to 2030 (0·2, <0·1–0·4), increasing with delayed 
benefits accrued to 2090. The benefit–cost dynamics of primary prevention were sensitive to the costs of different 
delivery approaches, uncertain epidemiological parameters regarding group A streptococcal pharyngitis and ARF, 
assumptions about long-term demographic and economic trends, and discounting.
Interpretation Increased coverage of interventions to control and manage RHD could accelerate progress towards 
eradication in AU member states. Gaps in local epidemiological data and particular components of the disease 
process create uncertainty around the level of benefits. In the short term, costs of secondary prevention and secondary 
and tertiary care for RHD are lower than for primary prevention, and benefits accrue earlier.
Funding World Heart Federation, Leona M and Harry B Helmsley Charitable Trust, and American Heart 
Association.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Although acute rheumatic fever (ARF) and rheumatic 
heart disease (RHD) are now rare in most high-income 
countries, they remain a major cause of cardiovascular 
disease in several regions, including Africa, where RHD 
causes more than 18 000 deaths per year.1 Africa is the 
region with the highest RHD prevalence in the world.2 
ARF is caused by an inflammatory process in some 
individuals after infection with group A streptococcus, 
and some people with ARF go on to develop RHD.3 Rates 
of ARF and RHD remain high in Africa in part because 
of living conditions associated with poverty, including 
household overcrowding, and inadequate levels of 
coverage of high-quality health care.4–6
Substantial evidence exists for cost-effective strategies 
to prevent and manage ARF and RHD in low-income 
and middle-income settings.7–9 The incidence of ARF 
dropped significantly in Cuba, Costa Rica, and Tunisia 
over periods coinciding with concerted campaigns 
improving coverage of primary and secondary 
prevention.10–12 Primary prevention through treatment 
of children with group A streptococcal pharyngitis 
with antibiotics—often benzathine penicillin G (BPG) 
injection—has typically been delivered through primary 
health care or in schools to make care accessible to 
achieve necessary coverage.11,13 Monthly BPG injection 
for secondary prevention is recommended for several 
years after a case of ARF involving carditis, with varied 
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duration depending partly on severity and age.14 
Management of heart failure and other sequelae of 
severe disease, assessment for eligibility for surgical 
intervention to repair or replace damaged heart valves, 
and postoperative anticoagulation and follow-up benefit 
from integrated care strategies,15 yet access to these 
services in Africa has been low. The Global Rheumatic 
Heart Disease Registry (REMEDY) study found high 
mortality (about 17%) over an initial 2-year period.16 Few 
patients in Africa who meet criteria for surgical heart 
valve repair or replacement receive it.17
The World Heart Federation (WHF) has advocated 
for greater political and financing commitments at the 
global and national levels to address RHD. Intense effort 
by groups on the African continent over the past 15 years 
has built global momentum in research and advocacy 
around RHD, although progress has not been rapid.18,19 
The Addis Ababa communiqué, which identified priority 
areas for action on RHD to address gaps in data, health 
systems, and policy, was endorsed by heads of state in the 
African Union (AU) in 2016.20 In 2017, member states of 
WHO adopted the RHD Resolution EB141.R1 at the 
World Health Assembly, calling for national, regional, 
and global actions to prevent and control ARF and RHD, 
with WHO and member states reporting on progress 
in 2021.21 The Pan African Society of Cardiology has 
convened a series of meetings with the WHO Regional 
Office for Africa (WHO/AFRO) to develop and endorse 
an RHD control programme that includes primary 
and secondary prevention.19,21,22 WHO/AFRO and partners 
have been exploring regional strategies for expanding 
integrated outpatient care for severe, chronic non-
communicable diseases (NCDs) at district hospitals 
(PEN-Plus) that includes preliminary echocardiographic 
RHD diagnosis, medical treatment of RHD, and 
postoperative anticoagulation.23–25 Multidisciplinary care 
during pregnancy continuing into the post-partum period 
reduced maternal and fetal mortality in women with 
cardiovascular disease in a pilot study in South Africa.26
Many solutions to addressing the RHD burden are 
known—the main barriers to their implementation 
are lack of prioritisation and resources. To encourage 
funding and collective action by countries, foundations, 
and development agencies, the WHF commissioned this 
investment case for RHD in the AU. In this investment 
case, we use evidence about the costs and effects of 
interventions to estimate the health impact and total 
costs of scaling up programmes in countries in the AU 
to operationally feasible levels over the next 10 years.27 
This work is intended to offer a way forward in 
addressing RHD as part of a broader NCD and injuries 
poverty agenda.28
Research in context
Evidence before this study
Rheumatic heart disease (RHD) remains a major cause of 
cardiovascular disease in the African Union (AU). We searched 
PubMed for English language articles published from database 
inception to Sept 14, 2020, using the terms “(rheumatic heart 
disease) AND (cost-effectiveness)”. Although there have been 
debates about particular strategies, there are multiple studies 
documenting the cost-effectiveness of primary prevention 
through the treatment of group A streptococcal pharyngitis 
with antibiotics, and secondary prevention through penicillin 
prophylaxis in people who have a history of acute rheumatic 
fever (ARF). Several countries have shown marked declines in 
RHD and ARF after implementing control programmes, mostly 
in middle-income settings. Some delivery models have shown 
success with the decentralisation of heart failure management, 
which includes RHD management and postoperative 
anticoagulation for mechanical heart valves and atrial 
fibrillation. Research and advocacy have built momentum 
towards the data, health system, and policy gaps that need to be 
addressed to eliminate RHD in Africa.
Added value of this study
We have built on the evidence from earlier epidemiological, 
costing, and cost-effectiveness studies to construct an 
investment case for scale-up of prevention and management 
strategies to work towards RHD elimination in the AU. 
We consider operationally plausible opportunities for 
investments in scaling up prevention, management, and 
surgical interventions and estimate the health impacts, cost, 
and returns on investment.
Implications of all the available evidence
We found potential for reducing RHD mortality by almost a 
third by increasing coverage of RHD interventions in regions of 
the AU to 2030. In the short term, investment in primary 
prevention would not avert a large number of deaths and 
would be costly because of the large number of childhood 
pharyngitis cases. Valve surgery, secondary prophylaxis, and 
medical management of established RHD cases through the 
Package of Essential Noncommunicable Disease Interventions-
Plus (PEN-Plus) delivery strategy require overlapping 
investments in equipment, human resources, and referral 
pathways, making their coordinated scale-up operationally 
logical. Monetised health benefits from increasing coverage of 
secondary prevention, management of severe disease, and 
valve surgeries exceeded costs in the 2021–30 timeframe using 
a full income approach to quantify benefits. Costs of primary 
prevention exceeded the value of benefits in the next decade. 
We found that benefits accrued up to 2090 produced 
favourable benefit–cost ratios with lower-cost delivery models 
and more favourable assumptions about uncertain 
epidemiological parameters, and that long-term benefit–cost 
ratios were highly influenced by discounting and assumptions 
about economic growth.
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Methods
Overview
We constructed a model to estimate the health effects, 
costs, and monetised health gains from increasing 
coverage of a set of RHD interventions in the scale-up 
period (2021–30) to estimate the benefit–cost ratio and net 
benefit. Our approach was informed by WHO guidance 
on investment cases for NCD prevention and control, as 
well as other recent global investment cases.27,29 We chose 
a 10-year period for its relevance to the policy cycle 
and alignment with the timeframe of the UN’s 2030 
Sustainable Development Goals.
Health impact model
We constructed a cohort state-transition model with 
an underlying demographic projection model. Tran sitions 
between states occurred in cycles of 1 year, with pre-
vention and treatment interventions altering the transition 
probabilities between states. For the demographic pro-
jections, we used levels of population and fertility estimates 
from the Global Burden of Disease Study (GBD) 20171 and 
trends in projected all-cause mortality and fertility from 
the UN Population Division World Population Prospects 
2019 revision (appendix p 6).30,31 We did analyses by region 
of the AU (appendix p 5) and aggregated to present results 
for the AU as a whole and its component regions.
The structure of our model of disease progression, with 
labels for particular parameters, is shown in figure 1. The 
model was split into two parts, with the first covering the 
disease process from pharyngitis to RHD incidence, and 
the second for the disease process from the development 
of RHD through its long-term consequences. The first 
part of the model used inputs from meta-analyses on 
pharyn gitis incidence among children and evidence 
on the risks of ARF and subsequent RHD collated by 
previous cost-effectiveness models to generate estimates 
of RHD incidence. The parameters governing pharyngitis 
and ARF were calibrated to the RHD incidence estimates 
from GBD 2017. These GBD 2017 estimates were informed 
by echocardiographic studies of RHD prevalence, which 
were more geographically specific and numerous than 
the studies on pharyngitis and ARF. The parameters 
describing movement between health states in the RHD 
part of the model were derived from a combination of 
GBD 2017 estimates and epidemiological studies from 
the literature in the AU. The parameters are described in 
further detail in the appendix (pp 8–21, 26–31). Atrial 
fibrillation and stroke are long-term sequelae often noted 
in relation to RHD. To retain a parsimonious model, we 
did not explicitly include these sequelae as health states 
in the model, although costs for managing patients with 
severe RHD include costs of additional therapies, such as 
anticoagulation, that these patients require. Pregnancy is 
a health state during which higher risk of complication 
or death from RHD can occur.32 Although we do not 
explicitly model the state of pregnancy, our model covers 
Figure 1: Health impact model structure
Health states are represented by white rectangles (death in grey rectangles) with transitions shown by blue arrows. Green rectangles represent interventions with black arrows showing the pathways on 
which the interventions act. Medically managed heart failure that no longer meets criteria for heart failure remains in the RHD with heart failure category because it has advanced irreversibly to severe 
disease. Populations occupy the health states in white and grey rectangles after each step of the model. The health states in the group A streptococcus and ARF portion of the model shown in pink are 
simplified in this figure, and there are more complex transitions occurring in each model step. The more detailed structure of the model is described in the appendix (pp 4, 8) with labels corresponding to 
transition probabilities. Postoperative management here is included with heart failure management, because these are services provided by the same providers within the health system in our model of 
scale-up. ARF=acute rheumatic fever. RHD=rheumatic heart disease.
Healthy Death from ARF
Group A streptococcal 
infection
Group A streptococcal 
infection
ARF remission
Mild RHD (asymptomatic) Severe RHD (with heart
failure)





Counselling on family 
planning (not modelled)









(from every health state)
Group A streptococcus and ARF model component RHD model component
See Online for appendix
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this population through management of severe disease 
generally. Increasing coverage of family planning services 
might have a larger population impact, mitigating RHD-
related complications during pregnancy. Further study 
examining the dynamics of disease progression in 
pregnancy and the cost and effectiveness of screening 
programmes to identify women with mild RHD would be 
required to create reliable estimates of potential costs and 
impact (appendix pp 24–25). We included family planning 
and prenatal consultation in women of reproductive age 
with RHD as interventions because of the importance of 
the risks from RHD during pregnancy, but the costs and 
effects were not estimated in our model.
The transition pathways on which the interventions 
act, the interventions, their effect sizes, and the baseline 
and target coverages are shown in figure 1 and table 1. 
We increased coverage over time from the starting 
coverage in 2020 to the target coverage in 2030. Starting 
coverage was based on sparse data and assumptions 
(appendix pp 26–31). We selected target coverage up to 
2030 based on operationally plausible goals, assuming 
sufficient levels of funding would be available (appendix 
pp 26–31). We estimated health benefits by comparing 
the results with intervention scale-up to the reference 
results under the baseline coverage levels (appendix 
p 31). We report incident cases of RHD averted, deaths 
averted from ARF and RHD, and percentage reductions 
in rates of incidence, prevalence, and deaths in the scale-
up scenario relative to the reference scenario.
Cost
We estimated costs for these interventions from the 
perspective of the health system by assembling published 
data on programmatic costs, estimates of health-care 
costs from the WHO Choosing Interventions that are 
Cost-Effective (WHO-CHOICE) project, and data on 
costs of medications and equipment that were necessary 
for each intervention.33–35 We followed the procedures 
recommended by the Global Health Cost Consortium to 
convert costs to 2019 US$.36 A full description of cost 
components and conversions is given in the appendix 
(pp 32–37).
For each of our projection scenarios, we calculated the 
net cost difference compared with the reference no scale-
up scenario to obtain the cost of scale-up (appendix p 32). 
We calculated costs shared between interventions (such 
as equipment used in multiple interventions) once to 
prevent double counting and represent these as shared 
costs between the relevant interventions.
Monetised health gains and benefit–cost ratio
Benefit–cost analysis has been previously used in 
cases for investment around health interventions.27,29,37 
To monetise health benefits, we used a full income 
approach, combining economic benefit through 
projected changes in gross domestic product (GDP) and 
in the value of the health itself.38 To quantify the value of 
health gained, we multiplied deaths averted by estimates 
of the value of a statistical life (VSL). We used an 
established approach to adjust a VSL estimate from the 
USA for the AU using per capita gross national income 
and assumptions about income elasticity.37 We estimated 
the projected increase in GDP by multiplying the 
projected population difference between the scale-up 
and baseline scenarios by the per capita GDP, adjusted 
for projected real growth. In addition, we estimated 




1 Primary prevention (treatment of group A 
streptococcal pharyngitis, awareness raising, 
strengthening supply chains, provider training)
Percentage of group A streptococcal 
pharyngitis cases treated in ages 5–15 years
ARF and all subsequent health states 68% (52–79) 15·0% (3·8) 40%
2a Secondary prevention (prophylactic penicillin 
after ARF with carditis—10 years or until age 
20 years, whichever longer)
Percentage of people with ARF treated with 
prophylactic penicillin
ARF and all subsequent health states 55% (8–78) 5·0% (1·3) 40%
2b Secondary prevention (prophylactic penicillin 
in asymptomatic RHD)
Percentage of people with asymptomatic RHD 
treated with prophylactic penicillin
Severe RHD and all subsequent health states 55% (7–78) 5·0% (1·3) 40%
3 Platforms for heart failure management and 
anticoagulation, including management 
during pregnancy
Percentage of people with heart failure from 
RHD having heart failure medically managed
Deaths or prevalence of people with severe 
RHD or RHD post-valve surgery
60% (30–80)* 8·0% (2·0) 55%
4 Cardiac surgery and postoperative care Percentage of people with heart failure from 
RHD aged 10–40 years receiving cardiac surgery 
and postoperative care
Deaths or prevalence of people with severe 
RHD or RHD post-valve surgery
85% (70–92)† 5·0% (1·3) 25%
5 Evaluation and counselling on family 
planning for women of reproductive age‡
Percentage of women of reproductive age with 
RHD desiring contraceptive method who have 
access
Severe RHD and all subsequent health states ·· 45·0% (5·0) 75%
Data are % reduction (95% uncertainty interval), % (SD), or %. ARF=acute rheumatic fever. RHD=rheumatic heart disease. *Mortality risk reduction assumed to last 4 years, because heart failure management is not 
curative. †Initial 3% operative mortality assumed. ‡Intervention included here because of the risk that RHD poses during pregnancy, but effects not modelled. References for and descriptions of coverage estimates 
and effect sizes are given in the appendix (pp 22, 28). 15% reduction in RHD incidence assumed over the period from factors related to living conditions—reductions distributed in pharyngitis and ARF parameters 
(appendix p 11). Postoperative management coverage assumed 100% among people who have received surgeries (assumed that surgeries not done without care in place for long-term management).
Table 1: Intervention effect sizes and baseline and target coverage by intervention
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the number of hospitalisations from ARF that would be 
averted by the scale-up of interventions and multiplied 
these by estimated costs of hospitalisations for these 
conditions. Using the estimated costs of intervention 
scale-up and economic benefits from these three 
components, we calculated the net benefits and benefit–
cost ratio. Given that policy makers might be interested 
in understanding the short-term versus long-term 
benefits of investment, we estimated the benefit–cost 
ratio for the 2021–30 period and the 2021–90 period by 
accruing the health benefits through 2090 from the 
costs of the initial 2021–30 investment. The calculations 
are described in detail in the appendix (pp 38–40). We 
report costs and benefits without discounting and 
benefit–cost ratios and net benefits with 3% discounting 
of benefits and costs.39
Uncertainty and sensitivity analyses
We examined uncertainty through probabilistic sensi-
tivity analysis and deterministic sensitivity analysis of 
particularly influential or uncertain parameters. For the 
probabilistic sensitivity analysis, we included uncertainty 
about the transition probabilities, intervention effect sizes, 
starting coverage estimates, and cost components in the 
model, creating 1000 draws of the probabilities from 
uncertainty distributions associated with each parameter 
and running the model for 1000 randomly combined 
draws. We took the 2·5th and 97·5th percentiles of the 
draws to report uncertainty intervals (UIs). The UIs we 
present should not be interpreted as precise 95% CIs 
given limitations in inputs and assumptions used to 
derive them (appendix pp 41–42), and we treated the 
uncertainty reported as a range of plausible values. This 
uncertainty analysis did not incorporate uncertainty about 
forecasted demographic trends or economic indicators, 
nor did it capture uncertainty in the structure of our 
disease model.
For certain parameters, we captured uncertainty 
through deterministic sensitivity analysis. For the main 
results, we assumed that 80% of ARF cases are preceded 
by symptomatic group A streptococcal pharyngitis, 
that children aged 5–15 years have about 2·3 cases of 
pharyngitis per year at the peak age with 10% from 
group A streptococcus, that the delivery model for 
primary prevention is through health centres, and that 
all interventions in table 1 are scaled from baseline 
to target coverage through 2030. We reported results 
from alternative scenarios that varied these parameters, 
and compared results using different strategies for 
calibrating the transition probabilities to severe disease 
and death. Given the costly nature of treating the large 
number of childhood cases of pharyngitis, we included 
an alternative delivery model for primary prevention 
with community health workers (CHWs). A 10-year 
modelling period does not fully capture the impact of 
prevention, and we included alternative scenarios to 
capture benefits over a longer period. More complete 
results from various sensitivity analyses are in the 
appendix (pp 47–56).
Presentation of results
We present results for primary prevention separately 
from other integrated interventions (secondary pro-
phylaxis, heart failure care, echocardiography, surgery, 
and postsurgical management), as well as combined with 
other interventions for several reasons. First, the delivery 
of primary prevention does not depend on the other 
RHD interventions from a health systems perspective. 
By contrast, there are shared human resources, 
equipment, and connections in the care cascade that 
strongly tie the other interventions together. For example, 
for a surgical programme to exist, it is necessary to have 
a programme established that can manage heart failure, 
determine eligibility for surgery using echocardiography, 
and manage anticoagulation after surgery. Second, 
primary prevention is delivered through primary health 
care at health centres or in the community, whereas the 
other interventions all require access to secondary or 
tertiary care. Although secondary pro phylaxis should 
be administered through primary care for patient 
accessibility, established referral pathways to more 
advanced care are necessary for initial diagnosis and 
monitoring through registries.
All analyses were done with R, version 3.6.1.
Role of the funding source
Members of the WHF contributed to the study’s design 
and interpretation. The other funders played no role in 
the study design, data collection, data analysis, data 






All interventions‡  
RHD incident cases averted 
(thousands)
187·2 (113·3 to 247·2) 184·5 (31·0 to 310·6) 361·5 (207·2 to 497·3)
RHD deaths averted (thousands) 0·8 (0·5 to 1·1) 59·5 (40·3 to 76·3) 60·0 (40·8 to 76·8)
ARF deaths averted (thousands) 7·2 (1·5 to 19·6) 7·1 (0·5 to 22·1) 13·9 (2·4 to 38·3)
Cost (billions, US$) 3·1 (1·9 to 4·3) 1·0 (0·7 to 1·2) 3·9 (2·7 to 5·1)
Cost per death averted 
(thousands, US$)
526·1 (155·2 to 1389·4) 14·8 (10·6 to 22·7) 54·4 (33·8 to 83·5)
Full income benefit (billions, US$) 0·5 (0·1 to 1·2) 4·5 (3·0 to 5·9) 4·9 (3·3 to 6·7)
Benefit–cost ratio to 2030 0·2 (<0·1 to 0·4) 4·7 (2·9 to 6·3) 1·3 (0·8 to 1·9)
Benefit–cost ratio to 2090§ 0·7 (0·4 to 1·1) 8·4 (4·8 to 12·1) 3·2 (1·9 to 4·7)
Net benefit (billions, US$) –2·1 (–3·1 to –1·2) 2·8 (1·6 to 3·9) 0·8 (–0·8 to 2·3)
Data are mean (95% UI). Monetary values presented in 2019 US$. Costs and full income benefits presented without 
discounting. Benefit–cost ratio, net benefits, and cost per death averted based on discounted costs and benefits. Results 
reported for primary prevention delivered through health centre-based treatment, and results for additional sensitivity 
analyses, including for community-based delivery of primary prevention, are reported in the appendix (pp 47–56). 
*Health centre-based pharyngitis treatment. †Secondary prophylaxis, diagnosis, case management, and cardiac surgery 
for rheumatic fever and rheumatic heart disease. ‡Primary, secondary, and tertiary management. §Calculated using costs 
of scale-up 2021–30 and benefits accrued 2021–90; should be interpreted with caution because strongly dependent on 
assumed discount rates and inherently uncertain long-term projections of economic indicators.
Table 2: Summary benefit and cost results from selected scenarios, 2021–30
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Results
Scale-up in coverage of primary prevention was estimated 
to reduce the projected age-standardised incidence of 
RHD in 2030 by 7·6% (UI 4·7–10·1) compared with the 
reference no scale-up scenario, averting 187 200 
(113 300–247 200) new cases of RHD from 2021 to 2030 
(table 2). The death rate from ARF was estimated to be 
reduced by 8·5% (5·3–11·3) in 2030 compared with the 
value for 2030 estimated in the reference scenario, but 
estimated reductions in the age-standardised prevalence 
of RHD (1·3%, 0·8–1·8) and death rates from RHD 
(0·6%, 0·4–0·8) were smaller. Scale-up of secondary 
prophylaxis and integrated secondary and tertiary care 
were estimated to reduce incidence of RHD by 6·7% 
(1·2–11·3) in 2030. The projected age-standardised death 
rate from RHD was estimated to be reduced by 30·4% 
(21·4–38·7) in 2030 compared with the reference value, 
averting 59 500 (40 300–76 300) RHD deaths from 2021 to 
2030.
Increases in coverage for all combined interventions 
to 2030 target levels were estimated to reduce the 
projected age-standardised death rate from RHD from 
2·1 deaths per 100 000 (UI 1·8–2·3) in the reference 
scenario in 2030 to 1·4 deaths per 100 000 (1·2–1·7; 
figure 2) in the intervention scenario, a reduction of 
30·7% (21·6–39·0). Cumulatively, we estimated 60 000 
(40 800–76 800) RHD deaths averted and 13 900 
(2400–38 300) ARF deaths averted from 2021 to 2030.
The total cost of scaling up all interventions from 2021 
to 2030 was estimated at $3·9 billion (UI 2·7–5·1; 
2019 US$). Whereas the cost per surgery was among 
the largest per-unit costs (appendix pp 34–35), the large 
number of cases of pharyngitis in the population caused 
the scale-up of primary prevention to be the largest 
component of the overall cost—$3·1 billion (1·9–4·3) on 
its own, more than 75% of the cost of all combined 
interventions. The components of the cost of scaling up 
interventions from 2021 to 2030 are shown in figure 3. 
Costs shared between multiple interventions because of 
overlaps in equipment and human resources made up a 
large portion of the costs outside of primary prevention 
(about 39%), as did surgery and postoperative care 
visits including anticoagulation (37%), with secondary 
prophylaxis visits and medication (21%) and heart failure 
management visits and medications (2%) making up the 
remainder.
Costs were sensitive to several key inputs. The number 
of cases of pharyngitis per year was a large determinant of 
the overall cost of primary prevention because each case 
leads to the cost of a health-care visit, which includes 
provider time. Primary prevention delivered through a 
CHW model had potential to substantially reduce the cost 
Figure 2: Impact of interventions scaled to target coverage on age-standardised rates of incidence, prevalence, and deaths from RHD, 2020–30
Rates age-standardised to 2017 age structure of population in the African Union. Uncertainty intervals in rates reflect uncertainty in underlying epidemiological 
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of primary prevention (from $3·1 billion [UI 1·9–4·3] 
to $1·3 billion [0·8–1·9], assuming CHWs would see 
12 clients per day with an initial visit for diagnosis 
and dispensation of oral antibiotics and a second for 
adherence support; appendix p 54).
The full income benefits from investing in all 
interventions—capturing increased economic activity 
and the intrinsic value of health—were estimated at 
$4·9 billion (UI 3·3 to 6·7). The majority (93%) of this 
benefit was from the VSL component. The benefit–cost 
ratio was estimated to be 1·3 (0·8 to 1·9) to 2030 with a 
3% annual discount rate on costs and benefits, or 3·2 
(1·9 to 4·7) accruing benefits of the increased 2021–30 
coverage to 2090. Scaling up primary prevention alone 
was estimated to result in a low benefit–cost ratio (0·2, 
<0·1–0·4) and a negative net benefit (–$2·1 billion, 
–3·1 to –1·2) because of high cost and low short-term 
mortality impact. The benefit–cost ratio was estimated 
to be higher (0·7, 0·4 to 1·1) with benefits accrued to 
2090. Scaling up other interventions without primary 
prevention was estimated to result in a higher benefit–
cost ratio (4·7, 2·9 to 6·3) and net benefit $2·8 billion 
(1·6 to 3·9) in the short term because of the more direct 
and immediate impact on deaths. Incorporating long-
term benefits through 2090, the estimated benefit–cost 
ratio grew to 8·4 (4·8 to 12·1) because of the effects of 
secondary prevention. The estimated long-term benefit–
cost ratios were sensitive to discount rates and strongly 
depended on assumptions about economic growth 
through 2090 used to project VSL estimates (appendix 
pp 38–40, 55).
The short-term benefit–cost ratio through 2030 for 
primary prevention was estimated to be higher using a 
CHW model of delivering care, assuming CHWs could 
see 12 clients per day (0·4, UI 0·1–0·9), but remained 
low overall without the long-term benefits accrued. We 
modelled a high benefit, low cost scenario in which 
primary prevention was delivered by CHWs seeing 
12 clients per day, children had one pharyngitis case 
per year with 10% from group A streptococcus, and 
coverage was increased to 100% in 2021, reverting to 0% 
coverage in 2031 to project benefits accrued to 2090. 
Under this scenario, the benefit–cost ratio to 2090 was 
estimated to be 4·2 (2·1–6·8). Projections to 2090 should 
be interpreted with caution (appendix pp 38–40, 55). 
Country-level and regional variation in epidemiology, 
demography, and economic productivity affects the 
estimated benefit–cost ratios (appendix pp 45–46, 56). 
Additional results for the various described scenarios are 
presented in the appendix (pp 47–56).
Discussion
We found substantial potential for reduction in cases of, 
and deaths from, RHD in the AU with scale-up in 
coverage of an evidence-informed bundle of related 
interventions from 2021 to 2030. Secondary prevention 
and treatment, targeting different stages of the disease 
process, are likely to avert substantial morbidity and 
mortality in the short term, whereas primary prevention 
is likely to accrue impact extending over a long time 
horizon. Key features of the RHD course and differing 
delivery strategies will influence cost and size of the 
effect of primary prevention.
Integrated prevention programmes have been linked 
to declines in ARF and RHD in parts of the AU and in 
other settings.11,12 However, evaluations have not been able 
to account for the effects of primordial prevention 
(improved living conditions) to isolate causal effects of 
specific interventions. Previous studies have suggested 
that prevention is cost-effective, although effects of 
primary prevention assumed in many cost-effectiveness 
studies are from specific populations in older trials among 
individuals presenting with pharyngitis.8,9,40 By contrast, 
our estimates of the benefit–cost ratio for primary 
prevention were relatively low. The ratio increased as we 
modelled benefits for a longer period, although the ratio 
remained comparatively low unless alternative cost 
and epidemiological assumptions were used (appendix 
pp 48–51, 54). The cost of primary prevention in our study 
was high, because it included the cost of increased health-
care visits by many children aged 5–15 years with non-
group A streptococcal pharyngitis and the treatment of 
some of these children based on the imperfect specificity 
of a clinical decision rule.8,41 The health benefits of primary 
prevention were also limited by the proportion of 
ARF cases that were assumed to occur among people 
with preceding symptomatic pharyngitis (assumed 80%, 
although varied in sensitivity analyses) and cases 
occurring outside the intervention’s target age range.
Figure 3: Cost of interventions scaled to target coverage, 2020–30
Costs in 2019 US$. Costs presented for scale-up of all interventions to target coverage. Shared costs for primary 
and secondary prophylaxis include mass media awareness and education campaign costs and costs of provider 
education, training, and mentorship to strengthen correct treatment of sore throat, referral of ARF for diagnosis, 
and administration of secondary prophylaxis at health centres. Shared costs for secondary prophylaxis, heart 
failure management, and surgery include first referral-level provider training and costs of equipment and supplies. 
ARF=acute rheumatic fever. RHD=rheumatic heart disease.
Primary prevention (treatment of sore throat)
Secondary prophylaxis (penicillin for ARF and mild RHD)
Heart failure management
Surgery and postoperative management
Shared costs: primary and secondary prophylaxis
Shared costs: equipment and training for secondary prophylaxis, 
heart failure, and surgery
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Better evidence on the epidemiology of group A 
streptococcal pharyngitis in the AU and feasibility and 
cost-effectiveness studies on primary prevention delivery 
models, including potentially less costly CHW models, 
might be critical for understanding the costs and 
population-level impact of primary prevention. Primary 
prevention delivered at health centres might be more 
costly and might not be able to reach coverage levels as 
high as CHW-based delivery because of additional patient 
barriers to accessing care. However, treatment with BPG 
delivered at health centres might be more effective than 
oral antibiotics, and eliminates the concerns about 
antimicrobial resistance that come with adherence to 
courses of oral antibiotics. Primary prevention for RHD 
has not traditionally been delivered by CHWs; pilot 
programmes would improve logistical assumptions and 
estimates of both cost and effectiveness. Access to 
penicillin for both primary and secondary prevention 
efforts has been a critical part of success stories in RHD 
control, yet cost and availability of BPG have sometimes 
been barriers to its consistent use.12,42
Operationally, systems for secondary prevention, 
heart failure management, and valve surgery are 
interdependent. Investment in strengthening referral 
systems between levels of the health system, decen-
tralising echo cardiography for diagnosis of RHD, 
strengthening BPG supply chains, training of providers 
at health centres to administer penicillin prophylaxis 
and refer patients for higher-level care when necessary, 
strengthening and developing cardiac surgery centres, 
building awareness and education through multisectoral 
RHD initiatives, and strengthening surveillance and 
registry systems would benefit the coverage and quality 
of the continuum of care from secondary prophylaxis 
through cardiac surgery.20 Availability of long-term 
postoperative follow-up maximises the benefit of valve 
surgery, so it is advan tageous for the scale-up of heart 
failure management and anticoagulation therapy to at 
least match the scale-up in cardiac surgery. Coordinated 
investment in facilities, equipment, medications, and 
human resources to provide integrated RHD services 
has been demonstrated through the PEN-Plus delivery 
model for severe, chronic NCDs such as type 1 and 
insulin-dependent type 2 diabetes, sickle cell disease, 
and advanced cardiovascular disease.23–25 The provider 
competencies needed for RHD management align with 
competencies required to manage other complex and 
chronic NCDs, including other causes of heart failure, 
creating an opportunity for integrated care and shared 
invest ments across disease priorities.15,43 Family planning 
services, preconception counselling and an option of 
safe abortion for women with RHD who might become 
pregnant, and adapted heart failure management 
strategies can reduce risk of maternal morbidity and 
mortality.26,44 Capacity for cardiac surgery in Africa has 
been growing, and although some continued investment 
in sending patients abroad for surgery might be 
necessary, there are several emerging cardiac surgery 
centres on the continent that would continue to grow 
with further investment and caseloads.45
There were several limitations to our modelling study. 
Data describing the complete epidemiological picture of 
ARF and RHD in the AU were lacking. We sought to 
anchor estimates to data from parts of the disease process 
with comparatively better evidence—eg, estimates of 
RHD incidence and prevalence from GBD 2017 informed 
by echocardiographic prevalence studies and charac-
terisations of cohorts with RHD across sites with 
registries in the AU (appendix pp 57–63). However, 
questions remain about the natural history of subclinical 
RHD cases, and national-level RHD mortality data in 
Africa are largely restricted to South Africa.1,46 We 
reported ranges to reflect uncertainty in some of the 
input parameters, although our reported intervals should 
be interpreted with care given the limitations in the 
uncertainty estimates of inputs (appendix p 41). There 
were ways in which our model simplified the disease 
process, not explicitly including stroke, atrial fibrillation, 
and pregnancy, which can result from or interact with 
RHD. Our goal was to create a model that used available 
parameter estimates and included components most 
critical for costing and health benefit projection, but that 
was parsimonious. The long-term benefit–cost ratios 
presented to 2090 should be interpreted with caution, 
because our model does not capture uncertainties 
about long-term economic and demographic changes. 
The approach for estimating economic productivity 
benefits of lives saved is limited and does not account 
for individuals’ likelihood to contribute economically; 
however, the VSL is roughly 30 times the GDP per capita 
and contributes far more to the monetised health 
benefits. We sought to transparently describe the effects 
of model parameters and assumptions through sensi-
tivity analyses, and we comment on limitations of specific 
components of the modelling throughout the appendix. 
This analysis shows a possible path for addressing RHD 
in the AU, although country-specific implementation 
strategies should be informed by more specific demo-
graphic and epidemio logical information and assessment 
of local health system factors.
Our study did not account for the effects of the current 
COVID-19 pandemic. Elective surgeries have been 
postponed in many countries, travel slowed or halted, and 
resources diverted to manage COVID-19. Given the 
link between living standards and ARF and RHD, 
and the projected increase of as many as 400 million 
additional people pushed under the $1·90 poverty line 
globally, COVID-19 will probably continue to set back 
progress on RHD, making scale-up of these interventions 
even more critical.47 Our analysis suggests that primary 
prevention is not a high priority for countries with severe 
resource constraints in the wake of COVID-19, particularly 
given the high costs. However, there are a number of 
benefits of primary prevention outside of RHD, including 
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preventing other sequelae of group A streptococcus 
and reducing inappropriate antimicrobial use. A compre-
hensive analysis of the benefits of primary prevention 
would likely find its benefits higher than its costs, but 
such an analysis was outside the scope of this study.48 
Investing in the integrated implementation of prevention, 
management, and surgical interventions to address 
RHD can strengthen health systems, decentralise care, 
and engage multiple sectors to avert large amounts of 
morbidity and mortality, provide returns in economic 
welfare exceeding the costs, and accelerate progress 
towards eliminating RHD in the AU.
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